Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft
Background: Bioresorbable vascular grafts (BVGs) can transform biologically into active blood vessels and represent an alternative to traditional synthetic conduits, which are prone to complications such as infection and thrombosis. Although platelet-derived growth factors and c-Kit positive cells p...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | JVS - Vascular Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666350320300043 |
| _version_ | 1818821435870674944 |
|---|---|
| author | Hideki Miyachi, MD, PhD Shuhei Tara, MD, PhD Satoru Otsuru, MD, PhD Tai Yi, MD Yong-Ung Lee, PhD Joseph D. Drews, MD Hidetaka Nakayama, PhD Shinka Miyamoto, MD, PhD Tadahisa Sugiura, MD, PhD Toshihiro Shoji, BA Christopher K. Breuer, MD Toshiharu Shinoka, MD, PhD |
| author_facet | Hideki Miyachi, MD, PhD Shuhei Tara, MD, PhD Satoru Otsuru, MD, PhD Tai Yi, MD Yong-Ung Lee, PhD Joseph D. Drews, MD Hidetaka Nakayama, PhD Shinka Miyamoto, MD, PhD Tadahisa Sugiura, MD, PhD Toshihiro Shoji, BA Christopher K. Breuer, MD Toshiharu Shinoka, MD, PhD |
| author_sort | Hideki Miyachi, MD, PhD |
| collection | DOAJ |
| description | Background: Bioresorbable vascular grafts (BVGs) can transform biologically into active blood vessels and represent an alternative to traditional synthetic conduits, which are prone to complications such as infection and thrombosis. Although platelet-derived growth factors and c-Kit positive cells play an important role in smooth muscle cell (SMC) migration and proliferation in vascular injury, atherosclerosis, or allograft, their roles in the vascular remodeling process of an arterial BVG remains unknown. Thus, we assessed the neottisue formation on arterial BVG remodeling by administrating imatinib, which is both a platelet-derived growth factor receptor kinase inhibitor and c-Kit receptor kinase inhibitor, in a murine model. Methods: BVGs were composed of an inner poly(L-lactic-co-ε-caprolactone) copolymer sponge layer and an outer electrospun poly(L-lactic acid) nanofiber layer, which were implanted into the infrarenal abdominal aortas of C57BL/6 mice. After graft implantation, saline or 100 mg/kg of imatinib was administrated intraperitoneally daily for 2 weeks (n = 20 per group). Five mice in each group were scheduled to be humanely killed at 3 weeks and 15 at 8 weeks, and BVGs were explanted for histologic assessments. Results: Graft patency during the 8-week observational period was not significantly different between groups (control, 86.7% vs imatinib, 80.0%; P > .999). Neotissue formation consisting of endothelialization, smooth muscle proliferation, and deposition of collagen and elastin was not observed in either group at 3 weeks. Similar endothelialization was achieved in both groups at 8 weeks, but thickness and percent area of neotissue formation were significantly higher in the control group than in the imatinib group, (thickness, 30.1 ± 7.2 μm vs 19.6 ± 4.5 μm [P = .001]; percent area, 9.8 ± 2.7% vs 6.8 ± 1.8% [P = .005]). Furthermore, SMC layer and deposition of collagen and elastin were better organized at 8 weeks in the control group compared with the imatinib group. The thickness of SMC layer and collagen fiber area were significantly greater at 8 weeks in the control group than in the imatinib group (P < .001 and P = .026, respectively). Because there was no difference in the inner diameter of explanted BVGs (831.7 ± 63.4 μm vs 841.8 ± 41.9 μm; P = .689), neotissue formation was thought to advance toward the outer portion of the BVG with degradation of the polymer scaffold. Conclusions: Imatinib attenuates neotissue formation during vascular remodeling in arterial bioresorbable vascular grafts (BVGs) by inhibiting SMC layer formation and extracellular matrix deposition. : Clinical Relevance: This study demonstrated that imatinib attenuated neotissue formation during vascular remodeling in arterial Bioresorbable vascular graft (BVG) by inhibiting smooth muscle cell formation and extracellular matrix deposition. In addition, as imatinib did not modify the inner diameter of BVG, neotissue advanced circumferentially toward the outer portion of the neovessel. Currently, BVGs have not yet been clinically applied to the arterial circulation. The results of this study are helpful for the design of BVG that can achieve an optimal balance between polymer degradation and neotissue formation. |
| first_indexed | 2024-12-18T23:08:09Z |
| format | Article |
| id | doaj.art-3c6ac0d5f4d545b39b0c37998a746a77 |
| institution | Directory Open Access Journal |
| issn | 2666-3503 |
| language | English |
| last_indexed | 2024-12-18T23:08:09Z |
| publishDate | 2020-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JVS - Vascular Science |
| spelling | doaj.art-3c6ac0d5f4d545b39b0c37998a746a772022-12-21T20:48:25ZengElsevierJVS - Vascular Science2666-35032020-01-0115767Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graftHideki Miyachi, MD, PhD0Shuhei Tara, MD, PhD1Satoru Otsuru, MD, PhD2Tai Yi, MD3Yong-Ung Lee, PhD4Joseph D. Drews, MD5Hidetaka Nakayama, PhD6Shinka Miyamoto, MD, PhD7Tadahisa Sugiura, MD, PhD8Toshihiro Shoji, BA9Christopher K. Breuer, MD10Toshiharu Shinoka, MD, PhD11Center for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, JapanCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, JapanCenter for Childhood Cancer and Blood Disease, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MdCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioQOL Research Center Laboratory, Gunze Limited, Ayabe-Shi, Kyoto, JapanCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Correspondence: Toshiharu Shinoka, MD, PhD, The Tissue Engineering Program and Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children's Hospital, 700 Children's Dr, T2294, Columbus, OH 43205Center for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OhioCenter for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children's Hospital, Columbus, OhioBackground: Bioresorbable vascular grafts (BVGs) can transform biologically into active blood vessels and represent an alternative to traditional synthetic conduits, which are prone to complications such as infection and thrombosis. Although platelet-derived growth factors and c-Kit positive cells play an important role in smooth muscle cell (SMC) migration and proliferation in vascular injury, atherosclerosis, or allograft, their roles in the vascular remodeling process of an arterial BVG remains unknown. Thus, we assessed the neottisue formation on arterial BVG remodeling by administrating imatinib, which is both a platelet-derived growth factor receptor kinase inhibitor and c-Kit receptor kinase inhibitor, in a murine model. Methods: BVGs were composed of an inner poly(L-lactic-co-ε-caprolactone) copolymer sponge layer and an outer electrospun poly(L-lactic acid) nanofiber layer, which were implanted into the infrarenal abdominal aortas of C57BL/6 mice. After graft implantation, saline or 100 mg/kg of imatinib was administrated intraperitoneally daily for 2 weeks (n = 20 per group). Five mice in each group were scheduled to be humanely killed at 3 weeks and 15 at 8 weeks, and BVGs were explanted for histologic assessments. Results: Graft patency during the 8-week observational period was not significantly different between groups (control, 86.7% vs imatinib, 80.0%; P > .999). Neotissue formation consisting of endothelialization, smooth muscle proliferation, and deposition of collagen and elastin was not observed in either group at 3 weeks. Similar endothelialization was achieved in both groups at 8 weeks, but thickness and percent area of neotissue formation were significantly higher in the control group than in the imatinib group, (thickness, 30.1 ± 7.2 μm vs 19.6 ± 4.5 μm [P = .001]; percent area, 9.8 ± 2.7% vs 6.8 ± 1.8% [P = .005]). Furthermore, SMC layer and deposition of collagen and elastin were better organized at 8 weeks in the control group compared with the imatinib group. The thickness of SMC layer and collagen fiber area were significantly greater at 8 weeks in the control group than in the imatinib group (P < .001 and P = .026, respectively). Because there was no difference in the inner diameter of explanted BVGs (831.7 ± 63.4 μm vs 841.8 ± 41.9 μm; P = .689), neotissue formation was thought to advance toward the outer portion of the BVG with degradation of the polymer scaffold. Conclusions: Imatinib attenuates neotissue formation during vascular remodeling in arterial bioresorbable vascular grafts (BVGs) by inhibiting SMC layer formation and extracellular matrix deposition. : Clinical Relevance: This study demonstrated that imatinib attenuated neotissue formation during vascular remodeling in arterial Bioresorbable vascular graft (BVG) by inhibiting smooth muscle cell formation and extracellular matrix deposition. In addition, as imatinib did not modify the inner diameter of BVG, neotissue advanced circumferentially toward the outer portion of the neovessel. Currently, BVGs have not yet been clinically applied to the arterial circulation. The results of this study are helpful for the design of BVG that can achieve an optimal balance between polymer degradation and neotissue formation.http://www.sciencedirect.com/science/article/pii/S2666350320300043Tyrosine kinase inhibitorSmooth muscle cellNeotissue formationVascular remodeling |
| spellingShingle | Hideki Miyachi, MD, PhD Shuhei Tara, MD, PhD Satoru Otsuru, MD, PhD Tai Yi, MD Yong-Ung Lee, PhD Joseph D. Drews, MD Hidetaka Nakayama, PhD Shinka Miyamoto, MD, PhD Tadahisa Sugiura, MD, PhD Toshihiro Shoji, BA Christopher K. Breuer, MD Toshiharu Shinoka, MD, PhD Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft JVS - Vascular Science Tyrosine kinase inhibitor Smooth muscle cell Neotissue formation Vascular remodeling |
| title | Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| title_full | Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| title_fullStr | Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| title_full_unstemmed | Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| title_short | Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| title_sort | imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft |
| topic | Tyrosine kinase inhibitor Smooth muscle cell Neotissue formation Vascular remodeling |
| url | http://www.sciencedirect.com/science/article/pii/S2666350320300043 |
| work_keys_str_mv | AT hidekimiyachimdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT shuheitaramdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT satoruotsurumdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT taiyimd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT yongungleephd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT josephddrewsmd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT hidetakanakayamaphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT shinkamiyamotomdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT tadahisasugiuramdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT toshihiroshojiba imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT christopherkbreuermd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft AT toshiharushinokamdphd imatinibattenuatesneotissueformationduringvascularremodelinginanarterialbioresorbablevasculargraft |